Shanghai Pharmaceutical Co Ltd (601607):製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C10112)
◆英語タイトル:Shanghai Pharmaceutical Co Ltd (601607) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10112
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年11月
◆ページ数:55
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:中国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥26,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥53,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥79,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Shanghai Pharmaceutical Co Ltd (Shanghai Pharma) is a manufacturer, retailer, wholesaler and distributor of healthcare products. The company carries out the research and development, manufacture and sale of pharmaceutical products for treating HER2 positive advanced breast cancer, systemic anti-infection, and antineoplastic drug and immunomodulator. It also offers pharmaceuticals for diseases and disorders of cardiovascular system, digestive and metabolism, neurological system, musculoskeletal system, and respiratory system. The company also provides distribution and supply chain solutions to pharmaceutical manufacturers and dispensers; operates retail pharmacy stores; and provides consulting services, assets management and other services. Shanghai Pharma also provides traditional Chinese medicines. The company operates through a group of subsidiaries in China. Shanghai Pharma is headquartered in Shanghai, China.

Shanghai Pharmaceutical Co Ltd (601607) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Shanghai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Shanghai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Shanghai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Shanghai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Shanghai Pharmaceutical Co Ltd, Medical Devices Deals, 2012 to YTD 2018 11
Shanghai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Shanghai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deal Details 14
Asset Purchase 14
Shanghai Pharma Acquires China Business from Cardinal Health for USD1.2 Billion 14
Private Equity 16
Ardian May Sell Riemser Pharma for USD494.3 Million 16
Partnerships 18
Biocad and Shanghai Pharma to Form Joint Venture 18
Bracco Imaging Enters into Agreement with Shanghai Pharma 19
Shanghai Pharma Forms Joint Venture with DHL International 20
Shanghai Fudan-Zhangjiang Renews Strategic Cooperation Agreement with Shanghai Pharmaceuticals 21
Shanghai Pharma to Form Joint Venture with Zhongxie Pharma 22
Shanghai Traditional Chinese Medicine Enters into Distribution Agreement with Shanghai Hutchison Pharma for Six Prescription Drug Products 23
Shanghai Pharma Enters Into R&D Agreement With Second Military Medical University To Develop New Medicine And Medical Devices 24
Equity Offering 25
Shanghai Pharma Raises USD400 Million in Private Placement of Shares 25
Adgero Biopharma Raises USD2 Million in Equity Financing 27
Shanghai Fudan-Zhangjiang Completes Private Placement Of Shares For US$25 Million 28
Acquisition 29
Shanghai Pharma to Acquire 26.34% Stake in Techpool Bio-Pharma from Takeda Pharma for USD143.4 Million 29
Shanghai Pharma Plans to Acquire 67.5% Stake in Yunnan Dali Kangya Biotech for USD43.8 Million 30
Shanghai Fudan-Zhangjiang Bio-Pharma Acquires 90% Stake in Shanghai Youni Biotech 31
Shanghai Pharmaceuticals Acquires Stakes in Two China-Based Pharma Companies for USD71 Million 32
Shanghai Pharma Acquires Additional 20% Stake In Chiatai Qingchun Bao Pharma For US$71 Million 33
Shanghai Pharma To Acquire Drug Development Company For US$2.4 Million 34
Shanghai Pharma To Acquire China International Pharma For Up To US$8 Million 35
Shanghai Pharma Acquires 79% Stake In Big Global From Dongying Pharma For US$99 Million 36
Shanghai No.1 Biochemical & Pharma Acquires Additional 10.99% Stake In Mergen Biotech From Excellent Hope For US$0.2 Million 37
Shanghai Pharma Completes Acquisition Of 70% Stake In Changzhou Kangli Pharma For US$33 Million 38
Shanghai Zhongxi Sunve Pharma Acquires 51% Stake In Shanghai Jinhe Bio-Technology 39
Shanghai Pharmaceutical Co Ltd – Key Competitors 40
Shanghai Pharmaceutical Co Ltd – Key Employees 41
Shanghai Pharmaceutical Co Ltd – Locations And Subsidiaries 42
Head Office 42
Other Locations & Subsidiaries 42
Affiliate 43
Recent Developments 45
Financial Announcements 45
May 02, 2018: Shanghai Pharmaceuticals Registered Growth of Over 30% 45
Oct 30, 2017: Shanghai Pharmaceuticals Realized Stable Results In the Third Quarter 47
Oct 30, 2017: Shanghai Pharmaceuticals Realized Stable Results In the Third Quarter Industrial Income Sustained High and Stable Growth Research and Development Capabilities Reaffirmed 48
Aug 28, 2017: Shanghai Pharmaceuticals Realized Stable and Healthy Growth in Interim Results 49
Jun 27, 2017: Shanghai Pharmaceuticals Grew Steady in 2017 Q1 51
Product News 52
03/09/2018: Shanghai Pharma Announce Clinical Approval for Hydroxytriptolide 52
Other Significant Developments 53
Jan 18, 2018: CBMG Accelerates Cell Therapy Manufacturing with GE Healthcare’s New Start-to-Finish Solution 53
Mar 21, 2017: Shanghai Pharmaceuticals Released 2016 Annual Results:Staying Proactive while Conforming to Reforms, 54
Appendix 55
Methodology 55
About GlobalData 55
Contact Us 55
Disclaimer 55

List of Tables
Shanghai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Shanghai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Shanghai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Shanghai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Shanghai Pharmaceutical Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 9
Shanghai Pharmaceutical Co Ltd, Medical Devices Deals, 2012 to YTD 2018 11
Shanghai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Shanghai Pharma Acquires China Business from Cardinal Health for USD1.2 Billion 14
Ardian May Sell Riemser Pharma for USD494.3 Million 16
Biocad and Shanghai Pharma to Form Joint Venture 18
Bracco Imaging Enters into Agreement with Shanghai Pharma 19
Shanghai Pharma Forms Joint Venture with DHL International 20
Shanghai Fudan-Zhangjiang Renews Strategic Cooperation Agreement with Shanghai Pharmaceuticals 21
Shanghai Pharma to Form Joint Venture with Zhongxie Pharma 22
Shanghai Traditional Chinese Medicine Enters into Distribution Agreement with Shanghai Hutchison Pharma for Six Prescription Drug Products 23
Shanghai Pharma Enters Into R&D Agreement With Second Military Medical University To Develop New Medicine And Medical Devices 24
Shanghai Pharma Raises USD400 Million in Private Placement of Shares 25
Adgero Biopharma Raises USD2 Million in Equity Financing 27
Shanghai Fudan-Zhangjiang Completes Private Placement Of Shares For US$25 Million 28
Shanghai Pharma to Acquire 26.34% Stake in Techpool Bio-Pharma from Takeda Pharma for USD143.4 Million 29
Shanghai Pharma Plans to Acquire 67.5% Stake in Yunnan Dali Kangya Biotech for USD43.8 Million 30
Shanghai Fudan-Zhangjiang Bio-Pharma Acquires 90% Stake in Shanghai Youni Biotech 31
Shanghai Pharmaceuticals Acquires Stakes in Two China-Based Pharma Companies for USD71 Million 32
Shanghai Pharma Acquires Additional 20% Stake In Chiatai Qingchun Bao Pharma For US$71 Million 33
Shanghai Pharma To Acquire Drug Development Company For US$2.4 Million 34
Shanghai Pharma To Acquire China International Pharma For Up To US$8 Million 35
Shanghai Pharma Acquires 79% Stake In Big Global From Dongying Pharma For US$99 Million 36
Shanghai No.1 Biochemical & Pharma Acquires Additional 10.99% Stake In Mergen Biotech From Excellent Hope For US$0.2 Million 37
Shanghai Pharma Completes Acquisition Of 70% Stake In Changzhou Kangli Pharma For US$33 Million 38
Shanghai Zhongxi Sunve Pharma Acquires 51% Stake In Shanghai Jinhe Bio-Technology 39
Shanghai Pharmaceutical Co Ltd, Key Competitors 40
Shanghai Pharmaceutical Co Ltd, Key Employees 41
Shanghai Pharmaceutical Co Ltd, Subsidiaries 42
Shanghai Pharmaceutical Co Ltd, Affiliate 43

List of Figures
Shanghai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Shanghai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Shanghai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Shanghai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Shanghai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Shanghai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Shanghai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Shanghai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Shanghai Pharmaceutical Co Ltd, Medical Devices Deals, 2012 to YTD 2018 11

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Shanghai Pharmaceutical Co Ltd (601607):製薬・医療:M&Aディール及び事業提携情報(Shanghai Pharmaceutical Co Ltd (601607) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆